2010
DOI: 10.1200/jco.2010.28.15_suppl.e14109
|View full text |Cite
|
Sign up to set email alerts
|

Phase II study of metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with refractory metastatic colorectal cancer (MCRC).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…As no oral irinotecan formulations have been approved, clinical data on frequent dosing with irinotecan are sparse. However, data from the few published studies seem to indicate that frequent dosing is well tolerated and possibly more efficacious than more protracted administration schedules [ 29 31 ].…”
Section: Discussionmentioning
confidence: 99%
“…As no oral irinotecan formulations have been approved, clinical data on frequent dosing with irinotecan are sparse. However, data from the few published studies seem to indicate that frequent dosing is well tolerated and possibly more efficacious than more protracted administration schedules [ 29 31 ].…”
Section: Discussionmentioning
confidence: 99%